42374-07-2

Upstream product

• 100-97-0 hexamethylenetetramine 
• 697-82-5 2,3,5-trimethylphenol 
• 74-90-8 hydrogen cyanide 
• 4885-02-3 Dichloromethyl methyl ether 
• 5779-72-6 2,4,5-trimethylbenzaldehyde 
• 50-00-0 formaldehyd 
• 95-63-6 1,2,4-Trimethylbenzene 

Downstream Products

• 527-35-5 2,3,5,6-tetramethylphenol 
• 99070-20-9 3-bromo-6-hydroxy-2,4,5-trimethyl-benzaldehyde 
• 383676-66-2 2-hydroxy-5-nitro-3,4,6-trimethylbenzaldehyde 
• 17362-16-2 4-bromo-2,3,5,6-tetramethylphenol 
• 105207-91-8 2-hydroxy-3,4,6-trimethyl-cinnamic acid 

Relevant academic research and scientific papers

INK COMPOSITION, INKJET RECORDING METHOD, PRINTED MATTER, AND HIGH-MOLECULAR-WEIGHT POLYMERIZATION INITIATOR

An ink composition contains (component A) a high-molecular-weight polymerization initiator having a weight-average molecular weight of equal to or greater than 1,000, (component B) a polymerizable compound, and (component C) a colorant, in which the component A has an acylphosphine oxide structure, and the acylphosphine oxide structure is linked to a main chain or a core of the component A on the side of an acyl group thereof.

Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: Discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent

G protein-coupled receptor 40 (GPR40)/free fatty acid receptor 1 (FFA1) is a free fatty acid (FFA) receptor that mediates FFA-amplified glucose-stimulated insulin secretion in pancreatic β-cells. We previously identified (2,3-dihydro-1-benzofuran-3-yl)acetic acid derivative 2 as a candidate, but it had relatively high lipophilicity. Adding a polar functional group on 2 yielded several compounds with lower lipophilicity and little effect on caspase-3/7 activity at 30 μM (a marker of toxicity in human HepG2 hepatocytes). Three optimized compounds showed promising pharmacokinetic profiles with good in vivo effects. Of these, compound 16 had the lowest lipophilicity. Metabolic analysis of 16 showed a long-acting PK profile due to high resistance to β-oxidation. Oral administration of 16 significantly reduced plasma glucose excursion and increased insulin secretion during an OGTT in type 2 diabetic rats. Compound 16 (TAK-875) is being evaluated in human clinical trials for the treatment of type 2 diabetes.

FUSED CYCLIC COMPOUNDS

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.

BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS

The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula (1). Wherein Z, X, R1, R2, R3, and R4 are as described in specification.

CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS

The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula (I). Wherein Z, X, R1, R2, R3, and R4 are as described in the specification.

Benzoxazepinones and their use as squalene synthase inhibitors

There is disclosed a compound represented by the formula [I]: wherein R1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, -X1-X2-Ar-X3-X4-COOH (wherein X1 and X4 are a bond or alkylene group, X2 and X3 are a bond, -O-, -S-, Ar is divalent aromatic group etc.), R2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.

Solid-phase synthesis: A linker for side-chain anchoring of arginine

A new linker based on a chroman system is described for the side-chain anchoring of Arg and other guanidine-containing molecules. The system is compatible with the Fmoc/tBu solid-phase strategy, because the release of the final product is achieved by treatment with TFA in the presence of scavengers.

o-Formylation of electron-rich phenols with dichloromethyl methyl ether and TiCl4

o-Formylation of electron-rich phenols is accomplished with dichloromethyl methyl ether and TiCl4. The reaction gives excellent yields, good regioselectivity, and does not leading to diformylation.